Search clinical trials for: synergoss Pxx

Total 324 results

Nobil Bio Ricerche srl

Unknown

CP009 SYNERGOSS PXX Observational

Mouth, Edentulous

Italy
HaEmek Medical Center, Israel

Unknown

Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia

Bladder Cancer

Israel
Changhai Hospital

Recruiting

Personalized Precision Diagnosis and Treatment of Pancreatic Cancer (PPDTPC)

Pancreatic Cancer

China
Medical Enterprises Europe B.V.

Withdrawn

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Bladder Cancer
University Hospital, Rouen

Not yet recruiting

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study (PEX-FREE)

Thrombotic Microangiopathies
Philips Respironics

Completed

Alice PDx User/Validation Extended Trial

Sleep Apnea | Sleep-Disordered Breathing

United States
University of Michigan

Completed

Pharmacogenomic Testing in Primary Care

Antidepressants Causing Adverse Effects in Therapeutic Use

United States
Cook Group Incorporated

Completed

Zilver PTX Drug-Eluting Peripheral Stent Study

Peripheral Arterial Disease

Germany, Switzerland
Cook Group Incorporated

Completed

Formula PTX Renal Stent Clinical Study

Renal Artery Stenosis

United Kingdom, Germany, Czechia, France
Duke University
National Institute of General Medical Sciences (NIGMS)

Completed

Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting

Pharmacogenetics

United States
Pluristem Ltd.

Completed

Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty

Total Hip Arthroplasty | Muscle Injury

Germany
Hannah Choe, MD
National Cancer Institute (NCI); Plexxikon

Terminated

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Acute Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Pyxis Oncology, Inc

Recruiting

Study of PYX-201 in Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, Spain, Belgium
Pluristem Ltd.

Terminated

Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

COVID | ARDS

Israel, Germany
Pluristem Ltd.

Completed

Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

Incomplete HCT (Hematopoietic Cell Transplantation)

United States, Israel
Palvella Therapeutics, Inc.

Active, not recruiting

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita (VALO-2)

Pachyonychia Congenita

United States
Canadian Center for Functional Medicine
University of British Columbia; InovoBiologic Inc.

Completed

Evaluation of Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX)

Blood Glucose, Postprandial | Appetite and Hunger, Suppression

Canada
Pluristem Ltd.

Completed

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

Peripheral Vascular Disease | Peripheral Artery Disease | Critical Limb Ischemia

United States
Pyxis Oncology, Inc

Recruiting

Study of PYX-106 in Solid Tumors

Solid Tumor

United States, Spain, Belgium
Ology Bioservices

Completed

Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder

Post Traumatic Stress Disorder

United States
Epix Pharmaceuticals, Inc.

Terminated

An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

Pulmonary Hypertension | COPD

United States
Glycemic Index Laboratories, Inc
Canadian Center for Functional Medicine; InovoBiologic Inc.

Completed

Reduction of the Glycemic Index by a Novel Viscous Polysaccharide

Blood Glucose, Postprandial

Canada
Cierra

Suspended

PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)

Patent Foramen Ovale

France, Germany, Belgium
Hoffmann-La Roche
Roche Diabetes Care Deutschland GmbH

Completed

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients. (PDMProValueDSP)

Type II Diabetes Mellitus

Germany
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)

Completed

An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years (P2P+IY)

Aggression

United States
Proviva Therapeutics, Inc.

Not yet recruiting

A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer
Prescient Therapeutics, Ltd.

Recruiting

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Advanced Cancer | PTCL

Australia
Pharmaxis

Completed

A Two-part Pharmacokinetic Study of PXS-5382A in Healthy Adult Males

Pharmacokinetics

Australia
Muğla Sıtkı Koçman University

Completed

Pentraxin-3 in Hysterectomy Patients

Abdominal Hysterectomy | Laparoscopic Hysterectomy
Brigham and Women's Hospital
CQuentia NGS, LLC

Withdrawn

Prospective Study to Evaluate the Clinical Utility of Perioperative Pharmacogenomic Testing

Perioperative/Postoperative Complications

United States
WideTrial, Inc.

Available

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

Critical Limb Ischemia (CLI)
Epix Pharmaceuticals, Inc.

Completed

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States
howard safran
Rhode Island Hospital; MaineHealth

Completed

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

Brain Tumor

United States
Hoffmann-La Roche
Roche Diabetes Care Deutschland GmbH

Completed

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients. (PDM-ProValueGP)

Diabetes Mellitus, Type 2

Germany
Mayo Clinic

Not yet recruiting

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: (PREPARE-Mayo)

Side Effect of Drug | Pharmacogenomic Drug Interaction | Drug Metabolism, Poor, CYP2D6-Related | Ineffective Drug Action | Drug Metabolism, Poor, CYP2C19-Related

United States
Cierra

Unknown

Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

Patent Foramen Ovale

Germany
Pluristem Ltd.

Completed

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Intermittent Claudication | Peripheral Artery Disease

United States, Germany, Korea, Republic of, Israel
Pluristem Ltd.

Unknown

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Critical Limb Ischemia (CLI)

Germany, United Kingdom, Hungary, United States, Bulgaria, Czechia, Israel, North Macedonia, Poland
Palvella Therapeutics, Inc.

Unknown

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Pachyonychia Congenita

United States
Duke University

Completed

Medication Therapy Management With Pharmacogenetic Testing

Pharmacogenetics | Medication Therapy Management

United States
Cierra

Completed

The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

Foramen Ovale, Patent

Germany
Spectral Diagnostics (US) Inc.

No longer available

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Septic Shock | Endotoxemia | COVID | Corona Virus Infection | Sepsis, Severe

United States
The Second Hospital of Anhui Medical University

Unknown

Comparison of Total Parathyroidectomy With and Without Autotransplantation

Secondary Hyperparathyroidism

China
Mahidol University

Recruiting

Efficacy and Safety of Fractional 1064-nm Picosecond Laser for Facial Skin Tightening

Laxity; Skin

Thailand
Cierra

Suspended

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness (Paradigm IV)

Stroke | Migraine | Transient Ischemic Attack | Decompression Illness | PFO

Germany
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients (Bright51)

Fabry Disease

Belgium, United States, United Kingdom, Italy, Czechia, Denmark, Norway
Pluristem Ltd.

Unknown

Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) (HS-ARS)

Ionizing Radiation Exposure
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Fabry Disease

United States, Netherlands, Australia, Hungary, United Kingdom, Canada, Czechia, Finland, France, Italy, Norway, Slovenia, Spain
Mayo Clinic

Completed

Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders

Gastrointestinal Diseases

United States
National Institute for Health Development, Estonia
European Social Fund; Ministry of the Interior, Estonia

Completed

Impact of PAX Good Behavior Game on Elementary School Students in Estonia (PAXGBGEE)

Mental Disorders | Mental Health Wellness 1

Search clinical trials for: synergoss Pxx

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations